oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Search Results: 1 - 4 of 4 matches for " Dylst "
All listed articles are free for downloading (OA Articles)
Page 1 /4
Display every page Item
Generic Medicine Pricing Policies in Europe: Current Status and Impact
Pieter Dylst,Steven Simoens
Pharmaceuticals , 2010, DOI: 10.3390/ph3030471
Abstract: Generic medicine pricing is an area of national responsibility of European Union countries. This article aims to present the current status and impact of generic medicine pricing policies in ambulatory care in Europe. The study conducts a literature review of policies relating to free-pricing systems, price-regulated systems, price differentiation, price competition and discounts, and tendering procedures; and a survey of European generic medicine pricing policies. Competition from Indian generic medicine manufacturers, European variation in generic medicine prices and competition between generic medicine manufacturers by discount suggest that the potential savings to health care payers and patients from generic medicines are not fully realized in Europe. One way of attaining these savings may be to move away from competition by discount to competition by price. Free-pricing systems may drive medicine prices downwards under specific conditions. In price-regulated systems, regulation may lower prices of originator and generic medicines, but may also remove incentives for additional price reductions beyond those imposed by regulation. To date, little is known about the current status and impact of tendering procedures for medicines in ambulatory care. In conclusion, the European experience suggests that there is not a single approach towards developing generic medicine pricing policies in Europe.
How can pharmacist remuneration systems in Europe contribute to generic medicine dispensing?
Dylst,Pieter; Vulto,Arnold; Simoens,Steven;
Pharmacy Practice (Internet) , 2012, DOI: 10.4321/S1886-36552012000100002
Abstract: generic medicines can generate larger savings to health care budgets when their use is supported by incentives on both the supply-side and the demand-side. pharmacists′ remuneration is one factor influencing the dispensing of generic medicines. objective: the aim of this article is to provide an overview of different pharmacist remuneration systems for generic medicines in europe, with a view to exploring how pharmacist remuneration systems can contribute to generic medicine dispensing. methods: data were obtained from a literature review, a master thesis in pharmaceutical care at the catholic university of leuven and a mailing sent to all members of the pharmaceutical group of the european union with a request for information about the local remuneration systems of community pharmacists and the possible existence of reports on discounting practices. results: pharmacists remuneration in most european countries consists of the combination of a fixed fee per item and a certain percentage of the acquisition cost or the delivery price of the medicines. this percentage component can be fixed, regressive or capped for very high-cost medicines and acts as a disincentive for dispensing generic medicines. discounting for generic medicines is common practice in several european countries but information on this practice tends to be confidential. nevertheless, data for belgium, france, the netherlands and united kingdom indicated that discounting percentages varied from 10% to 70% of the wholesale selling price. conclusion: pharmacists can play an important role in the development of a generic medicines market. pharmacists should not be financially penalized for dispensing generic medicines. therefore, their remuneration should move towards a fee-for-performance remuneration instead of a price-dependent reimbursement which is currently used in many european countries. such a fee-for-performance remuneration system provides a stimulus for generic medicines dispensing as pharmac
How can pharmacist remuneration systems in Europe contribute to generic medicine dispensing?
Dylst P,Vulto A,Simoens S
Pharmacy Practice (Granada) , 2012,
Abstract: Generic medicines can generate larger savings to health care budgets when their use is supported by incentives on both the supply-side and the demand-side. Pharmacists’ remuneration is one factor influencing the dispensing of generic medicines.Objective: The aim of this article is to provide an overview of different pharmacist remuneration systems for generic medicines in Europe, with a view to exploring how pharmacist remuneration systems can contribute to generic medicine dispensing.Methods: Data were obtained from a literature review, a Master thesis in Pharmaceutical Care at the Catholic University of Leuven and a mailing sent to all members of the Pharmaceutical Group of the European Union with a request for information about the local remuneration systems of community pharmacists and the possible existence of reports on discounting practices.Results: Pharmacists remuneration in most European countries consists of the combination of a fixed fee per item and a certain percentage of the acquisition cost or the delivery price of the medicines. This percentage component can be fixed, regressive or capped for very high-cost medicines and acts as a disincentive for dispensing generic medicines. Discounting for generic medicines is common practice in several European countries but information on this practice tends to be confidential. Nevertheless, data for Belgium, France, the Netherlands and United Kingdom indicated that discounting percentages varied from 10% to 70% of the wholesale selling price.Conclusion: Pharmacists can play an important role in the development of a generic medicines market. Pharmacists should not be financially penalized for dispensing generic medicines. Therefore, their remuneration should move towards a fee-for-performance remuneration instead of a price-dependent reimbursement which is currently used in many European countries. Such a fee-for-performance remuneration system provides a stimulus for generic medicines dispensing as pharmacists are not penalized for dispensing them but also needs to account for the loss of income to pharmacists from prohibiting discounting practices
Reference pricing systems in Europe: characteristics and consequences
Pieter Dylst, PharmD,Professor Steven Simoens, MSc, PhD,Professor Arnold G Vulto, PharmD, PhD
Generics and Biosimilars Initiative Journal , 2012,
Abstract: Introduction: A reference pricing system is a system that establishes a common reimbursement level or reference price for a group of interchangeable medicines, i.e. the reference group. This article provides an overview of the different characteristics of the different reference pricing systems in Europe. Additionally, the impact of reference pricing on price competition, generic medicine use, pharmaceutical expenditure and health outcome will be discussed.Methods: Studies relevant for this article were found by means of a literature review. A survey was carried out to document the current status of reference pricing systems in Europe. Survey data were collected from member associations of the European Generic medicines Association in the context of their 2011 survey of European drug retail markets.Results: Many European governments have introduced reference pricing systems. Reference pricing systems reduce medicine prices but not always below the reference price, increase the use of medicines priced at or below the reference price, generate savings in pharmaceutical expenditure that tend to be limited to the short term, and do not seem to adversely affect health outcomes.Conclusion: Reference pricing is a popular policy for governments to contain pharmaceutical expenditures and seems to be effective in the different European countries.
Page 1 /4
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.